RxDoctor Payments Data

Kerry Moose, NP

Nurse Practitioner · Washington, DCNPI 1366748931

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,198 of the $1,707 with a category attached, or 70.2%. 12 manufacturers reported payments, led by Integra Lifesciences Corporation at 49.1% of the total. Reporting peaked in 2024 at $886 and has fallen 83.8% since, to $144 in 2025. Among nurse practitioner clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,707in general payments, 2019–2025

Across 43 payments — averaging $39.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$839
  • Smith+Nephew$282
  • Polynovo North America LLC$174
  • Organogenesis Inc.$147
  • Next Science LLC$112
  • Bone Support Inc.$44
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$1,19870%
  • Other$50930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 90th percentile of 224 nurse practitioner providers in District of Columbia.

See all nurse practitioner providers in District of Columbia

Medicare billing

Part B allowed, 2024
$28,728
Medicare patients
177
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gentamicin Sulfate25$884
Ammonium Lactate33$732
Doxycycline Hyclate26$354
Triamcinolone Acetonide17$114

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →